Latest Peptide News
Peptide News — page 3
Retatrutide Cardiovascular Risk Biomarkers Improve in New Analysis
Researchers reporting in Diabetes, Obesity & Metabolism describe improvements in retatrutide cardiovascular risk biomarkers in adults with obesity, with and without type 2 diabetes. It is the kind of result that shapes expectations for a drug still years from any approval — and it is not the same thing as an outcomes trial.
GLP-1 Gastroparesis Reviewed as Aspiration Questions Persist
Two new publications tackle the same underlying problem from different ends: a PLOS One systematic review of GLP-1 gastroparesis cases, and an Anaesthesia letter on gastric contents and aspiration risk after semaglutide cessation. Both matter to anyone on an incretin drug who has a procedure coming up.
Compounded Tirzepatide Facial Nodules Case Report Draws a Rebuttal
A dermatology case report attributing compounded tirzepatide facial nodules to inflammation has drawn a published rebuttal arguing that infection and biofilm were never ruled out. The exchange is a useful window into how thin the evidence still is when a compounded GLP-1 product and a cosmetic filler are in the same patient.
Tirzepatide Combination Therapy Trials: Four New Add-On Studies
Registry records posted in the second week of August 2026 show a cluster of tirzepatide combination therapy trials and semaglutide add-on studies, where the approved drug is the floor and the experimental agent has to prove it adds something. One Roche study even withdraws tirzepatide partway through to see what holds.
Semaglutide Alcohol Use Disorder Trial Enrolls 622 Veterans
The largest test yet of a GLP-1 receptor agonist for drinking has opened enrollment: a VA-sponsored semaglutide alcohol use disorder trial seeking 622 participants. It follows a smaller federally funded phase 2 study and observational reports on smoking and mood in another patient population.
Retatrutide Grey Market Tested: Australian Study Checks Labels
A research letter in Drug and Alcohol Review reports laboratory analysis of vials sold under the retatrutide name in Australia — a direct look at what circulates in the retatrutide grey market. It lands while the compound itself is still years from any approval decision, with a 4,500-participant liver outcomes trial now recruiting.
Compounded Glutathione Recall Over Elevated Endotoxin Levels
An Austin, Texas compounding pharmacy has pulled specified lots of an injectable antioxidant preparation after its own testing flagged a contaminant that sterility testing does not catch. The compounded glutathione recall reaches the patient level, which means vials already dispensed to individuals are covered.